STOCK TITAN
  1. Home
  2. News
  3. CMND

Clearmind Medicine Inc. Common Shares - CMND STOCK NEWS

Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).

Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.

Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.

Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.

Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.

Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.

For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

News

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Rhea-AI Summary
Clearmind Medicine Inc. (CMND) files a patent application for 3-MMC to treat eating disorders, potentially revolutionizing the weight loss industry. The company aims to address major health issues with novel psychedelic-derived therapeutics, targeting a lucrative market with significant growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
News

Clearmind Medicine CEO Issues Letter to Shareholders

Rhea-AI Summary
Clearmind Medicine Inc. (Nasdaq:CMND) announces significant progress in developing CMND-100, a groundbreaking MEAI-based formula, for treating alcohol use disorder (AUD) without inducing hallucinations. The Israeli Ministry of Health approved the Phase I/IIa clinical trial for CMND-100, showcasing promising pre-clinical results. Clearmind achieved various milestones in 2023, including FDA meetings, forming a Data and Safety Monitoring Board, securing IRB Approval, and partnering with renowned institutions for clinical trials. The company also unveiled positive outcomes in obesity research, collaborated with pharmaceutical leaders, and expanded its patent portfolio. Looking forward to 2024, Clearmind aims to initiate the Phase I/IIa trial for AUD, enhance strategic alliances, advance obesity research, and introduce an MEAI-based alcohol substitute, promising significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.86%
Tags
none
-
News

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Rhea-AI Summary
Clearmind Medicine Inc. submits its tenth patent application under the PCT in collaboration with SciSparc for a novel composition to prevent and treat depression. The global depression and anxiety disorders treatment market size is projected to reach USD 41.83 billion by 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
News

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Rhea-AI Summary
Clearmind Medicine Inc. receives divisional patent approval from China National Intellectual Property Administration for regulating binge behaviors with primary amine aminoindan compounds, enhancing its IP protection in the psychedelic space. The company's innovative molecule, MEAI, shows promise in treating Alcohol Use Disorder and binge drinking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
News

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Rhea-AI Summary
Clearmind Medicine Inc. receives approval to commence phase I/IIa clinical trial for alcohol use disorder patients using proprietary CMND-100 oral capsule. The trial aims to evaluate safety, pharmacokinetics, and efficacy of the novel psychedelic-derived therapeutic in reducing alcohol consumption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
clinical trial
-
News

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Rhea-AI Summary
Clearmind Medicine Inc. has received approval for the voluntary delisting of its common shares from the Canadian Securities Exchange (CSE) while maintaining its listing on the NASDAQ Capital Market under the symbol CMND. The company aims to streamline its trading process, enhance liquidity, and benefit shareholder value by focusing on a single marketplace.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
none
News

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Rhea-AI Summary
Clearmind Medicine Inc. announces the submission of three new patent applications under the international Patent Cooperation Treaty (PCT) in collaboration with SciSparc Ltd. The applications focus on novel compositions of MDMA, Ibogaine, and Ketamine with PEA, enhancing the company's IP protection in the psychedelic space. Clearmind now holds 27 granted patents and 24 pending patent applications across 15 patent families, solidifying its position in the industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Rhea-AI Summary
Clearmind Medicine Inc. receives approval to commence phase I/IIa clinical trial for alcohol use disorder patients using proprietary psychedelic MEAI-based CMND-100 oral capsule. The trial aims to evaluate safety, pharmacokinetics, and preliminary efficacy in reducing drinking patterns and cravings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
clinical trial
-
News

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Rhea-AI Summary
Clearmind Medicine Inc. submits three patent applications under the PCT for novel psychedelic-derived therapeutics in collaboration with SciSparc Ltd., strengthening its IP portfolio. The company now holds 27 granted patents and 24 pending patent applications across 15 patent families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.07%
Tags
none
News

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Rhea-AI Summary
Clearmind Medicine Inc. has been granted divisional patent approval by the China National Intellectual Property Administration, expanding its IP protection in the psychedelic space. The company's IP portfolio consists of fifteen utility patent families, including patents and applications in major jurisdictions such as the US, Europe, China, and India. The flagship molecule, MEAI, has shown promising results in regulating binge behaviors and alcohol consumption, offering potential treatment for Alcohol Use Disorder and binge drinking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none

FAQ

What is the current stock price of Clearmind Medicine Common Shares (CMND)?

The current stock price of Clearmind Medicine Common Shares (CMND) is $1.35 as of November 1, 2024.

What is the market cap of Clearmind Medicine Common Shares (CMND)?

The market cap of Clearmind Medicine Common Shares (CMND) is approximately 5.6M.

What is Clearmind Medicine Inc.'s primary area of focus?

Clearmind Medicine Inc. focuses on the discovery and development of novel psychedelic-derived therapeutics to address widespread and under-treated health problems, particularly alcohol use disorder (AUD).

What is CMND-100?

CMND-100 is Clearmind's flagship MEAI-based compound aimed at treating alcohol use disorder. It has shown promising pre-clinical results in reducing binge drinking without causing hallucinations.

What recent clinical developments has Clearmind made?

The Israeli Ministry of Health recently approved a Phase I/IIa clinical trial for CMND-100 to treat alcohol use disorder, marking a significant milestone in its development.

What are the key features of Clearmind's intellectual property portfolio?

Clearmind's intellectual property portfolio includes eighteen patent families and 27 granted patents, with recent additions focusing on treatments for alcohol use disorder, cocaine addiction, and obesity-related disorders.

What strategic collaborations has Clearmind entered into?

Clearmind has entered exclusive licensing agreements with the Hebrew University of Jerusalem and Yissum Research Development Company, enriching its portfolio with psychedelic compounds for treating addiction and mental health disorders.

What is Clearmind's MEAI-based alcohol substitute beverage program?

Clearmind is developing a proprietary, ethanol-free MEAI-based alcohol substitute beverage. This product aligns with the growing trend towards no- and low-alcohol consumption and aims to offer a health-focused alternative.

Where are Clearmind's shares traded?

Clearmind's shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under the symbol 'CWY0'.

How can I contact Clearmind Medicine Inc. for more information?

For more information, you can visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

What is Clearmind's approach to intellectual property?

Clearmind is committed to expanding and protecting its intellectual property by filing additional patents and remaining opportunistic regarding the acquisition of new IP assets.

How does Clearmind ensure the safety of its novel compounds?

Clearmind's novel compounds undergo rigorous pre-clinical and clinical trials to ensure safety and efficacy before potential commercialization.

Stock CMND logo
Clearmind Medicine Inc. Common Shares

Nasdaq:CMND

CMND Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CMND Stock Data

5.58M
4.06M
4.09%
5.34%
Biotechnology
Healthcare
Link
United States of America
Vancouver